F. R. , R is a postdoc fellow supported by the university of Rouen Normandie, Rouen, France and the Normandie region

C. Girmenia and A. P. Iori, An update on the safety and interactions of antifungal drugs in stem cell transplant recipients, Expert Opin Drug Saf, vol.2017, issue.3, pp.329-339

S. Bang, E. Edell, A. O. Eghrari, and J. D. Gottsch, Treatment with voriconazole in 3 eyes with resistant acanthamoeba keratitis, Am J Ophthalmol, issue.1, pp.66-69, 2010.

A. Austin, T. Lietman, and J. Rose-nussbaumer, Update on the management of infectious keratitis, Ophthalmology, vol.2017, issue.11, pp.1678-1689

W. Sponsel, N. Chen, D. Dang, G. Paris, J. Graybill et al., Topical voriconazole as a novel treatment for fungal keratitis, Antimicrob Agents Chemother, vol.50, issue.1, pp.262-268, 2006.

L. Qu, L. Li, and H. Xie, Corneal and aqueous humor concentrations of amphotericin b using three different routes of administration in a rabbit model, Ophthalmic Res, issue.3, pp.153-158, 2010.

J. Gueudry, L. Goff, L. Compagnon, P. Lefevre, S. Colasse et al., Evaluation of voriconazole anti-acanthamoeba polyphaga in vitro activity, rat cornea penetration and efficacy against experimental rat acanthamoeba keratitis, J Antimicrob Chemother, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02316685

N. Sharma, P. Sahay, P. K. Maharana, D. Singhal, G. Saluja et al., Management algorithm for fungal keratitis: The tst (topical, systemic, and targeted therapy) protocol, Cornea, vol.2019, issue.2, pp.141-145

G. A. Vemulakonda, S. M. Hariprasad, W. F. Mieler, R. A. Prince, G. K. Shah et al., Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans, Arch Ophthalmol, vol.126, issue.1, pp.18-22, 2008.

A. B. Clode, J. L. Davis, J. Salmon, T. M. Michau, and B. C. Gilger, Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses, Am J Vet Res, vol.67, issue.2, pp.296-301, 2006.

W. E. Sponsel, J. R. Graybill, H. L. Nevarez, and D. Dang, Ocular and systemic posaconazole(sch-56592) treatment of invasive fusarium solani keratitis and endophthalmitis, Br J Ophthalmol, vol.86, issue.7, pp.829-830, 2002.

F. Lamoureux, T. Duflot, J. B. Woillard, D. Metsu, T. Pereira et al., Impact of cyp2c19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections, Int J Antimicrob Agents, vol.2016, issue.2, pp.124-131

M. Cahane, B. Simon, G. J. Barequet, I. S. Grinbaum, A. Diamanstein-weiss et al., Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin, Br J Ophthalmol, vol.88, issue.1, pp.22-24, 2004.

C. L. Halliday, S. C. Chen, S. E. Kidd, S. Van-hal, B. Chapman et al., Antifungal susceptibilities of non-aspergillus filamentous fungi causing invasive infection in australia: Support for current antifungal guideline recommendations, Int J Antimicrob Agents, vol.2016, issue.4, pp.453-458

K. Uchida, N. Yokota, and H. Yamaguchi, In vitro antifungal activity of posaconazole against various pathogenic fungi, Int J Antimicrob Agents, vol.18, issue.2, pp.167-172, 2001.

G. Morace, L. Polonelli, and G. Group, Voriconazole activity against clinical yeast isolates: A multicentre italian study, Int J Antimicrob Agents, vol.26, issue.3, pp.247-253, 2005.

M. A. Pfaller, S. A. Messer, R. J. Hollis, R. N. Jones, and S. P. Group, Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin b against 239 clinical isolates of aspergillus spp. And other filamentous fungi: Report from sentry antimicrobial surveillance program, Antimicrob Agents Chemother, vol.46, issue.4, pp.1032-1037, 2000.

N. Sharma, J. Chacko, T. Velpandian, J. S. Titiyal, R. Sinha et al., Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis, Ophthalmology, vol.2013, issue.4, pp.677-681

S. Narayana, T. Krishnan, S. Ramakrishnan, P. P. Samantaray, A. Austin et al., Mycotic antimicrobial localized injection (malin): A randomized clinical trial evaluating intrastromal injection of voriconazole, Ophthalmology, 2019.

E. M. Agency, Posaconazole, scientific discussion, 2005.

A. Al-hatmi, A. Bonifaz, S. Ranque, G. Sybren-de-hoog, P. E. Verweij et al., Current antifungal treatment of fusariosis, Int J Antimicrob Agents, issue.3, pp.326-332, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01789209

D. Todokoro, T. Suzuki, T. Tamura, K. Makimura, H. Yamaguchi et al., Efficacy of luliconazole against broad-range filamentous fungi including fusarium solani species complex causing fungal keratitis, Cornea, vol.2019, issue.2, pp.238-242

J. Maertens, O. A. Cornely, A. J. Ullmann, W. J. Heinz, G. Krishna et al., Phase 1b study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease, Antimicrob Agents Chemother, vol.2014, issue.7, pp.3610-3617

L. Qu, L. Li, and H. Xie, Toxicity and pharmacokinetics of intrastromal injection of amphotericin b in a rabbit model, Curr Eye Res, vol.39, issue.4, pp.340-347, 2014.

E. Garcia-valenzuela and C. D. Song, Intracorneal injection of amphothericin b for recurrent fungal keratitis and endophthalmitis, Arch Ophthalmol, issue.12, pp.1721-1723, 2005.